{"id":1123,"date":"2021-11-05T22:59:00","date_gmt":"2021-11-06T02:59:00","guid":{"rendered":"https:\/\/paragoninstitute.org\/index.php\/2021\/11\/05\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/"},"modified":"2024-04-19T16:22:40","modified_gmt":"2024-04-19T20:22:40","slug":"whats-taking-the-fda-so-long-on-covid-drug-molnupiravir","status":"publish","type":"post","link":"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/","title":{"rendered":"What\u2019s Taking the FDA So Long on COVID Drug Molnupiravir?"},"content":{"rendered":"\r\n

On\u00a0October 1, pharmaceutical companies\u00a0Merck and Ridgeback Biotherapeutics<\/a>\u00a0announced that their investigational oral antiviral drug Molnupiravir reduced the risk of hospitalization or death by about 50 percent compared with placebo for patients with mild or moderate COVID-19. Now the breakthrough drug from the two American companies has been approved \u2014 in the United Kingdom. Americans will have to wait at least a month more.<\/p>\r\n\r\n\r\n\r\n

The drug is so exciting because it will be the first effective antiviral pill against COVID-19. Remdesivir, the only FDA-approved antiviral for COVID-19, must be administered intravenously in a hospital or in a similar medical setting, making it much more cumbersome and expensive to utilize. Monoclonal antibody treatments are expensive, hard to manufacture, and must also be administered intravenously. Molnupiravir would be the first treatment that patients could take at home.<\/p>\r\n\r\n\r\n\r\n

To continue reading, go to the original article<\/a> at National Review.<\/p>\r\n","protected":false},"excerpt":{"rendered":"

On\u00a0October 1, pharmaceutical companies\u00a0Merck and Ridgeback Biotherapeutics\u00a0announced that their investigational oral antiviral drug Molnupiravir reduced the risk of hospitalization or death by about 50 percent compared with placebo for patients…<\/p>\n","protected":false},"author":3,"featured_media":5159,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[754],"tags":[706,387],"external-media-outlet":[798],"featured":[],"location":[],"publication-type":[717],"acf":[],"yoast_head":"\nWhat\u2019s Taking the FDA So Long on COVID Drug Molnupiravir?<\/title>\n<meta name=\"description\" content=\"Molnupiravir reduced the risk of hospitalization or death by about 50 percent compared with placebo for patients with mild or moderate COVID.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"What\u2019s Taking the FDA So Long on COVID Drug Molnupiravir?\" \/>\n<meta property=\"og:description\" content=\"Molnupiravir reduced the risk of hospitalization or death by about 50 percent compared with placebo for patients with mild or moderate COVID.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/\" \/>\n<meta property=\"og:site_name\" content=\"Paragon Health Institute\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-06T02:59:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-19T20:22:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Dr. Joel Zinberg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"What\u2019s Taking the FDA So Long on COVID Drug Molnupiravir?\" \/>\n<meta name=\"twitter:description\" content=\"Molnupiravir reduced the risk of hospitalization or death by about 50 percent compared with placebo for patients with mild or moderate COVID.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Joel Zinberg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/\",\"url\":\"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/\",\"name\":\"What\u2019s Taking the FDA So Long on COVID Drug Molnupiravir?\",\"isPartOf\":{\"@id\":\"https:\/\/paragoninstitute.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp\",\"datePublished\":\"2021-11-06T02:59:00+00:00\",\"dateModified\":\"2024-04-19T20:22:40+00:00\",\"author\":{\"@id\":\"https:\/\/paragoninstitute.org\/#\/schema\/person\/41b77f32c6e25fc8e53850a28b09f2ff\"},\"description\":\"Molnupiravir reduced the risk of hospitalization or death by about 50 percent compared with placebo for patients with mild or moderate COVID.\",\"breadcrumb\":{\"@id\":\"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/#primaryimage\",\"url\":\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp\",\"contentUrl\":\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp\",\"width\":1920,\"height\":1080,\"caption\":\"IStock 1213293784 10\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/paragoninstitute.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"What\u2019s Taking the FDA So Long on COVID Drug Molnupiravir?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/paragoninstitute.org\/#website\",\"url\":\"https:\/\/paragoninstitute.org\/\",\"name\":\"Paragon Health Institute\",\"description\":\"Health Policy Solutions Americans Can Trust\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/paragoninstitute.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/paragoninstitute.org\/#\/schema\/person\/41b77f32c6e25fc8e53850a28b09f2ff\",\"name\":\"Dr. Joel Zinberg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/paragoninstitute.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2023\/11\/joel-zinberg.webp\",\"contentUrl\":\"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2023\/11\/joel-zinberg.webp\",\"caption\":\"Dr. Joel Zinberg\"},\"description\":\"Joel M. Zinberg, M.D., J.D. is the Director of the Public Health and American Well-Being Initiative at Paragon Health Institute, and a\u00a0senior fellow with the Competitive Enterprise Institute. A native New Yorker, he recently completed two years as\u00a0General Counsel and Senior Economist at the Council of Economic Advisers\u00a0in the Executive Office of the President. Dr. Zinberg has practiced general and oncologic surgery in New York for nearly 30 years at the Mount Sinai Hospital and Icahn School of Medicine, where he remains an\u00a0Associate Clinical Professor of Surgery. He has been involved with health policy issues and the interaction between law and medicine for his entire career. For 10 years, Dr. Zinberg taught as a lecturer at the Columbia University Law School, where he created a course on the legal, policy and ethical issues surrounding organ transplantation. He served for many years on the New York State Board of Professional Medical Conduct and on Mount Sinai\u2019s Ethics Committee and Institutional Review Board. He is a past President and Trustee of the New York County Medical Society, and between 2015 and 2017, served as a visiting scholar at the American Enterprise Institute. Dr. Zinberg has written for publications as varied as the Journal of the American Medical Association, the Bulletin of the American College of Surgeons, The Wall Street Journal, City Journal, and law reviews, and authored book chapters on legal and policy issues associated with organ transplantation. Dr. Zinberg earned his B.A. in economics with High Honors, Phi Beta Kappa, from Swarthmore College, his J.D. degree from the Yale Law School, and his M.D. from the Columbia University College of Physicians and Surgeons.\",\"url\":\"https:\/\/paragoninstitute.org\/author\/joel-zinberg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"What\u2019s Taking the FDA So Long on COVID Drug Molnupiravir?","description":"Molnupiravir reduced the risk of hospitalization or death by about 50 percent compared with placebo for patients with mild or moderate COVID.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/","og_locale":"en_US","og_type":"article","og_title":"What\u2019s Taking the FDA So Long on COVID Drug Molnupiravir?","og_description":"Molnupiravir reduced the risk of hospitalization or death by about 50 percent compared with placebo for patients with mild or moderate COVID.","og_url":"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/","og_site_name":"Paragon Health Institute","article_published_time":"2021-11-06T02:59:00+00:00","article_modified_time":"2024-04-19T20:22:40+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp","type":"image\/webp"}],"author":"Dr. Joel Zinberg","twitter_card":"summary_large_image","twitter_title":"What\u2019s Taking the FDA So Long on COVID Drug Molnupiravir?","twitter_description":"Molnupiravir reduced the risk of hospitalization or death by about 50 percent compared with placebo for patients with mild or moderate COVID.","twitter_image":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp","twitter_misc":{"Written by":"Dr. Joel Zinberg","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/","url":"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/","name":"What\u2019s Taking the FDA So Long on COVID Drug Molnupiravir?","isPartOf":{"@id":"https:\/\/paragoninstitute.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/#primaryimage"},"image":{"@id":"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/#primaryimage"},"thumbnailUrl":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp","datePublished":"2021-11-06T02:59:00+00:00","dateModified":"2024-04-19T20:22:40+00:00","author":{"@id":"https:\/\/paragoninstitute.org\/#\/schema\/person\/41b77f32c6e25fc8e53850a28b09f2ff"},"description":"Molnupiravir reduced the risk of hospitalization or death by about 50 percent compared with placebo for patients with mild or moderate COVID.","breadcrumb":{"@id":"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/#primaryimage","url":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp","contentUrl":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2021\/11\/iStock-1213293784_10.webp","width":1920,"height":1080,"caption":"IStock 1213293784 10"},{"@type":"BreadcrumbList","@id":"https:\/\/paragoninstitute.org\/public-health\/whats-taking-the-fda-so-long-on-covid-drug-molnupiravir\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/paragoninstitute.org\/"},{"@type":"ListItem","position":2,"name":"What\u2019s Taking the FDA So Long on COVID Drug Molnupiravir?"}]},{"@type":"WebSite","@id":"https:\/\/paragoninstitute.org\/#website","url":"https:\/\/paragoninstitute.org\/","name":"Paragon Health Institute","description":"Health Policy Solutions Americans Can Trust","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/paragoninstitute.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/paragoninstitute.org\/#\/schema\/person\/41b77f32c6e25fc8e53850a28b09f2ff","name":"Dr. Joel Zinberg","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/paragoninstitute.org\/#\/schema\/person\/image\/","url":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2023\/11\/joel-zinberg.webp","contentUrl":"https:\/\/paragoninstitute.org\/wp-content\/uploads\/2023\/11\/joel-zinberg.webp","caption":"Dr. Joel Zinberg"},"description":"Joel M. Zinberg, M.D., J.D. is the Director of the Public Health and American Well-Being Initiative at Paragon Health Institute, and a\u00a0senior fellow with the Competitive Enterprise Institute. A native New Yorker, he recently completed two years as\u00a0General Counsel and Senior Economist at the Council of Economic Advisers\u00a0in the Executive Office of the President. Dr. Zinberg has practiced general and oncologic surgery in New York for nearly 30 years at the Mount Sinai Hospital and Icahn School of Medicine, where he remains an\u00a0Associate Clinical Professor of Surgery. He has been involved with health policy issues and the interaction between law and medicine for his entire career. For 10 years, Dr. Zinberg taught as a lecturer at the Columbia University Law School, where he created a course on the legal, policy and ethical issues surrounding organ transplantation. He served for many years on the New York State Board of Professional Medical Conduct and on Mount Sinai\u2019s Ethics Committee and Institutional Review Board. He is a past President and Trustee of the New York County Medical Society, and between 2015 and 2017, served as a visiting scholar at the American Enterprise Institute. Dr. Zinberg has written for publications as varied as the Journal of the American Medical Association, the Bulletin of the American College of Surgeons, The Wall Street Journal, City Journal, and law reviews, and authored book chapters on legal and policy issues associated with organ transplantation. Dr. Zinberg earned his B.A. in economics with High Honors, Phi Beta Kappa, from Swarthmore College, his J.D. degree from the Yale Law School, and his M.D. from the Columbia University College of Physicians and Surgeons.","url":"https:\/\/paragoninstitute.org\/author\/joel-zinberg\/"}]}},"_links":{"self":[{"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/posts\/1123"}],"collection":[{"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/comments?post=1123"}],"version-history":[{"count":2,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/posts\/1123\/revisions"}],"predecessor-version":[{"id":3592,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/posts\/1123\/revisions\/3592"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/media\/5159"}],"wp:attachment":[{"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/media?parent=1123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/categories?post=1123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/tags?post=1123"},{"taxonomy":"external-media-outlet","embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/external-media-outlet?post=1123"},{"taxonomy":"featured","embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/featured?post=1123"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/location?post=1123"},{"taxonomy":"publication-type","embeddable":true,"href":"https:\/\/paragoninstitute.org\/wp-json\/wp\/v2\/publication-type?post=1123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}